Balancing is important throughout your life, and Zibrio has the tools and tips for you to use to stay centered. Pexels

In her postdoctoral work at NASA, Katharine Forth and her colleague were tasked with finding a new way to track the balance of astronauts on the moon.

"The machines typically used for balance measurement can be as large as a telephone booth, so we invented a new way to measure postural control using a much smaller mechanism that fit inside a moon boot," Forth says.

She didn't know it at the time, but working on this technology would lead her to create Zibrio, The Balance Company with her colleague, Erez Lieberman Aiden.

Zibrio is a health company that aims to be the gold standard of measuring balance. The Zibrio scale calculates users' weight like a typical scale and rates their balance on scale of 1 to 10.

The scale gathers data from your weight, your postural control, your muscles and other factors to calculate the rating. Andrea Case-Rogers, chief experience officer at Zibrio, describes a perfect rating of 10 as elusive for most, or "Simone Biles on a good day."

After seeing their rating, users can identify any problems and start taking steps to improve their balance. Zibrio will also come with a smartphone app, so users can track their balance, any fluctuations and progress over a long-term period.

By using the scale and app together, users can gain a greater understand of what in their lifestyle is helping versus hurting their balance.

From space to the marketplace
After co-founding Zibrio together in 2015, Forth and Aiden have taken the company a long way since then.

Zibrio is a finalist for the 2019 SXSW Pitch in the health and wearables category. In 2015, the company was part of the Texas Medical Center's TMCx medical devices cohort. Both programs highlight the innovative technology being used as well as the big impact that Zibrio could have for both consumers and clinicians.

Zibrio already has conducted clinical trials all over Houston by working with Memorial Hermann and UT Physicians, and the company is currently focused on fundraising. Forth and her team of five will use these funds to get the scale and smartphone app consumer-ready and launched.

The commercial launch for both the scale and app is planned for later this year.

"We're currently finalizing the design with the manufacturer, so they can make the scale available commercially," Forth says. "Since 2015, we've been fundraising, building prototype scales and conducting clinical trials."

Finding balance at any age
A common misconception is that our balance deteriorates in older age. In actuality, a lifetime of behavior and activity affects our balance in later years. Falls are the leading cause of accidental death and unexpected injuries in older adults.

"If you have been mostly sedentary your whole life, by the time you hit your later years, your lower limb strength is weakened affecting your ability to move." Forth says, "so many factors feed into your balance, which means there are so many things that can be done to lower your fall risk."

When Forth and her team ran a balance program at a senior living facility, they halved the number of falls in two years. By creating an awareness of balance, they were able to drive changed behaviors in the seniors, in turn, improving their balance.

According to Case-Rogers, Zibrio is bringing the balance conversation to people in 60s and 70s who want to keep their lifestyle and not deal with mobility and health issues later. They want to show investors that there is a market for wellness product like Zibrio among older people.

Zibrio will sponsor the National Senior Games, the largest multi-sport competition for seniors in the world, this summer in Albuquerque. With over 10,000 athletes, Forth and her team are excited to introduce Zibrio to a larger audience.

Forth firmly believes balance measurements should be a part of routine wellness exams and home self-monitoring, especially in later years.

"When athletes stand on a scale and see their number, it's like a light goes on in their heads and they realize how important balance is," says Forth. "That's what I love, we have this great product that opens up the conversation about and is really helping people in middle age and beyond."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.